ClinicalTrials.gov
ClinicalTrials.gov Menu

Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00368199
Recruitment Status : Completed
First Posted : August 24, 2006
Last Update Posted : February 26, 2018
Sponsor:
Collaborator:
Funding: Stichting Internationaal Parkinson Fonds, The Netherlands
Information provided by (Responsible Party):
Wim Weber, Maastricht University Medical Center

Brief Summary:
The purpose of the study is to determine the sensitivity and specificity of transcranial duplex scanning (TCD) and single photon emission computer tomography (SPECT) in patients suspected of having Idiopathic Parkinson Disease (PD) or Atypical Parkinson Syndromes (APS) with as golden standard the clinical diagnosis after 2-year follow-up.

Condition or disease
Parkinson's Disease Parkinsonian Syndrome Multiple System Atrophy Supranuclear Palsy, Progressive Essential Tremor Vascular Parkinsonism Drug Induced Parkinsonism

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 196 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diagnostic Value Transcranial Duplex Scanning and Single Photon Emission Tomography in Patients Suspected of Having Idiopathic Parkinson Disease or Atypical Parkinson Syndromes
Actual Study Start Date : September 1, 2006
Actual Primary Completion Date : September 18, 2008
Actual Study Completion Date : September 15, 2012





Primary Outcome Measures :
  1. Concordance of hyperechogenic SN with clinical diagnosis of Parkinson's [ Time Frame: 24 months ]
    Hyperechogenic substabtia nigra (SN) was assessed at initial visit and after 2 years, patients were re-examined by two movement disorder specialist neurologists for a final clinical diagnosis that served as a surrogate gold standard for our study.


Biospecimen Retention:   None Retained
no biocpsicmens


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
250 Patients with unclear parkinsonism at the outpatient clinic
Criteria

Inclusion Criteria:

  • Patients with unclear parkinsonism at the outpatient clinic

Exclusion Criteria:

  • Known diagnosis at presentation
  • Life expectation of less than two years because of a non neurological disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00368199


Locations
Netherlands
Maastricht University Medical Center
Maastricht, PO Box 5800, Netherlands, 6202 AZ
Sponsors and Collaborators
Maastricht University Medical Center
Funding: Stichting Internationaal Parkinson Fonds, The Netherlands
Investigators
Principal Investigator: Wim EJ Weber, MD PhD Maastricht University Medical Center

Additional Information:
Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Wim Weber, Associate Professor of Neurology, Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT00368199     History of Changes
Other Study ID Numbers: 1-Vlaar
First Posted: August 24, 2006    Key Record Dates
Last Update Posted: February 26, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Dataset is published with PeerJ
Time Frame: Is availabel
Access Criteria: Publicly available
URL: https://peerj.com/articles/2037

Keywords provided by Wim Weber, Maastricht University Medical Center:
single photon emission computer tomography (SPECT)
transcranial sonography
transcranial duplex scanning
parkinson's disease
atypical parkinson syndromes
parkinsonism
parkinsonian
diagnostic
progressive supranuclear paralysis

Additional relevant MeSH terms:
Syndrome
Parkinson Disease
Atrophy
Essential Tremor
Parkinsonian Disorders
Multiple System Atrophy
Shy-Drager Syndrome
Supranuclear Palsy, Progressive
Parkinson Disease, Secondary
Disease
Pathologic Processes
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Pathological Conditions, Anatomical
Primary Dysautonomias
Autonomic Nervous System Diseases
Hypotension
Vascular Diseases
Cardiovascular Diseases
Ophthalmoplegia
Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Paralysis
Neurologic Manifestations
Eye Diseases